One recent report found that acquired chemoresistance in SCLC was controlled through an epigenetic regulator, the EZH2-SLFN11 axis, not through emergence of recurrent gene mutations or changes in copy number (16). This evidence concerns the gene SLFN11 and small cell lung carcinoma.